FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048389430> ?p ?o ?g. }

• W3048389430 endingPage "65" @default.
• W3048389430 startingPage "58" @default.
• W3048389430 abstract "Abstract Objective Acromegaly is associated with impaired quality of life (QoL). We investigated the effects of biochemical control of acromegaly by growth hormone receptor antagonism vs somatostatin analog therapy on QoL. Design Cross‐sectional. Patients 116 subjects: n = 55 receiving a somatostatin analog (SSA group); n = 29 receiving pegvisomant (PEG group); n = 32 active acromegaly on no medical therapy (ACTIVE group). Measurements Acromegaly QoL Questionnaire (AcroQoL), Rand 36‐Item Short Form Survey (SF‐36) and Gastrointestinal QoL Index (GIQLI); fasting glucose, insulin and IGF‐1 levels (LC/MS, Quest Diagnostics). Results There were no group differences in mean age, BMI or sex [(whole cohort mean ± SD) age 52 ± 14 years, BMI 30 ± 6 kg/m 2 , and male sex 38%]. Mean IGF‐1 Z‐scores were higher in ACTIVE (3.9 ± 1.0) vs SSA and PEG, which did not differ from one another (0.5 ± 0.7 and 0.5 ± 0.7, P < .0001 vs ACTIVE). Eighty‐three per cent of PEG previously received somatostatin analogs, which had been discontinued due to lack of efficacy (52%) or side effects (41%). There were no differences in the four QoL primary end‐points (AcroQoL Global Score, SF‐36 Physical Component Summary Score, SF‐36 Mental Health Summary Score and GIQLI Global Score) between SSA and PEG. Higher HbA1c, BMI and IGF‐1 Z‐scores were associated with poorer QoL in several domains. Conclusion Our data support a comparable QoL in patients receiving pegvisomant vs somatostatin analogs, despite the fact that the vast majority receiving pegvisomant did not respond to or were not able to tolerate somatostatin analogs." @default.
• W3048389430 created "2020-08-18" @default.
• W3048389430 creator A5007527084 @default.
• W3048389430 creator A5013107494 @default.
• W3048389430 creator A5022118831 @default.
• W3048389430 creator A5039551750 @default.
• W3048389430 creator A5046245100 @default.
• W3048389430 creator A5047720768 @default.
• W3048389430 creator A5052169338 @default.
• W3048389430 creator A5053205115 @default.
• W3048389430 creator A5062686177 @default.
• W3048389430 creator A5066793063 @default.
• W3048389430 creator A5067016582 @default.
• W3048389430 creator A5072195548 @default.
• W3048389430 creator A5084067564 @default.
• W3048389430 date "2020-09-11" @default.
• W3048389430 modified "2023-10-18" @default.
• W3048389430 title "Effects of growth hormone receptor antagonism and somatostatin analog administration on quality of life in acromegaly" @default.
• W3048389430 cites W1584075755 @default.
• W3048389430 cites W1969427273 @default.
• W3048389430 cites W1976977515 @default.
• W3048389430 cites W1977937731 @default.
• W3048389430 cites W1986921101 @default.
• W3048389430 cites W1988158211 @default.
• W3048389430 cites W1998207473 @default.
• W3048389430 cites W2035030554 @default.
• W3048389430 cites W2037972154 @default.
• W3048389430 cites W2052734273 @default.
• W3048389430 cites W2061422223 @default.
• W3048389430 cites W2068554324 @default.
• W3048389430 cites W2069476119 @default.
• W3048389430 cites W2075383821 @default.
• W3048389430 cites W2113016432 @default.
• W3048389430 cites W2114461739 @default.
• W3048389430 cites W2123997600 @default.
• W3048389430 cites W2126750918 @default.
• W3048389430 cites W2129145699 @default.
• W3048389430 cites W2145493248 @default.
• W3048389430 cites W2147795491 @default.
• W3048389430 cites W2148385751 @default.
• W3048389430 cites W2153055499 @default.
• W3048389430 cites W2158162115 @default.
• W3048389430 cites W2160234571 @default.
• W3048389430 cites W2160707094 @default.
• W3048389430 cites W2162692537 @default.
• W3048389430 cites W2595162177 @default.
• W3048389430 cites W2599226646 @default.
• W3048389430 cites W2607031541 @default.
• W3048389430 cites W2895716383 @default.
• W3048389430 cites W2900973516 @default.
• W3048389430 cites W2944111718 @default.
• W3048389430 cites W2983185477 @default.
• W3048389430 cites W800658251 @default.
• W3048389430 doi "https://doi.org/10.1111/cen.14309" @default.
• W3048389430 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32779234" @default.
• W3048389430 hasPublicationYear "2020" @default.
• W3048389430 type Work @default.
• W3048389430 sameAs 3048389430 @default.
• W3048389430 citedByCount "5" @default.
• W3048389430 countsByYear W30483894302022 @default.
• W3048389430 countsByYear W30483894302023 @default.
• W3048389430 crossrefType "journal-article" @default.
• W3048389430 hasAuthorship W3048389430A5007527084 @default.
• W3048389430 hasAuthorship W3048389430A5013107494 @default.
• W3048389430 hasAuthorship W3048389430A5022118831 @default.
• W3048389430 hasAuthorship W3048389430A5039551750 @default.
• W3048389430 hasAuthorship W3048389430A5046245100 @default.
• W3048389430 hasAuthorship W3048389430A5047720768 @default.
• W3048389430 hasAuthorship W3048389430A5052169338 @default.
• W3048389430 hasAuthorship W3048389430A5053205115 @default.
• W3048389430 hasAuthorship W3048389430A5062686177 @default.
• W3048389430 hasAuthorship W3048389430A5066793063 @default.
• W3048389430 hasAuthorship W3048389430A5067016582 @default.
• W3048389430 hasAuthorship W3048389430A5072195548 @default.
• W3048389430 hasAuthorship W3048389430A5084067564 @default.
• W3048389430 hasBestOaLocation W30483894302 @default.
• W3048389430 hasConcept C126322002 @default.
• W3048389430 hasConcept C134018914 @default.
• W3048389430 hasConcept C159110408 @default.
• W3048389430 hasConcept C2776297358 @default.
• W3048389430 hasConcept C2777433750 @default.
• W3048389430 hasConcept C2778886798 @default.
• W3048389430 hasConcept C2779951463 @default.
• W3048389430 hasConcept C2984496839 @default.
• W3048389430 hasConcept C71315377 @default.
• W3048389430 hasConcept C71924100 @default.
• W3048389430 hasConceptScore W3048389430C126322002 @default.
• W3048389430 hasConceptScore W3048389430C134018914 @default.
• W3048389430 hasConceptScore W3048389430C159110408 @default.
• W3048389430 hasConceptScore W3048389430C2776297358 @default.
• W3048389430 hasConceptScore W3048389430C2777433750 @default.
• W3048389430 hasConceptScore W3048389430C2778886798 @default.
• W3048389430 hasConceptScore W3048389430C2779951463 @default.
• W3048389430 hasConceptScore W3048389430C2984496839 @default.
• W3048389430 hasConceptScore W3048389430C71315377 @default.
• W3048389430 hasConceptScore W3048389430C71924100 @default.
• W3048389430 hasFunder F4320307765 @default.
• W3048389430 hasFunder F4320308347 @default.

• next